Henry Schein, Inc. (NASDAQ:HSIC) Shares Sold by Vanguard Group Inc.

Vanguard Group Inc. lessened its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 0.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 14,725,518 shares of the company's stock after selling 108,397 shares during the quarter. Vanguard Group Inc. owned approximately 11.81% of Henry Schein worth $1,019,006,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. FMR LLC boosted its position in Henry Schein by 7.8% during the third quarter. FMR LLC now owns 3,280,890 shares of the company's stock valued at $239,177,000 after purchasing an additional 237,888 shares in the last quarter. Southpoint Capital Advisors LP lifted its position in shares of Henry Schein by 30.0% during the third quarter. Southpoint Capital Advisors LP now owns 2,600,000 shares of the company's stock valued at $189,540,000 after buying an additional 600,000 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Henry Schein by 1.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,191,677 shares of the company's stock valued at $82,464,000 after buying an additional 16,616 shares in the last quarter. ING Groep NV grew its position in shares of Henry Schein by 34.1% in the 4th quarter. ING Groep NV now owns 1,163,087 shares of the company's stock worth $80,486,000 after buying an additional 295,785 shares during the last quarter. Finally, Stifel Financial Corp raised its stake in shares of Henry Schein by 1.2% during the 3rd quarter. Stifel Financial Corp now owns 1,122,455 shares of the company's stock worth $81,827,000 after acquiring an additional 13,180 shares in the last quarter. 96.62% of the stock is currently owned by hedge funds and other institutional investors.

Henry Schein Price Performance

NASDAQ HSIC traded up $0.46 during trading hours on Wednesday, hitting $69.53. 186,355 shares of the company's stock traded hands, compared to its average volume of 1,567,323. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 0.82. The firm's 50-day moving average is $74.42 and its 200-day moving average is $72.67. Henry Schein, Inc. has a 52-week low of $63.67 and a 52-week high of $82.49. The company has a market capitalization of $8.63 billion, a PE ratio of 28.58, a PEG ratio of 2.13 and a beta of 0.84.

Henry Schein (NASDAQ:HSIC - Get Free Report) last posted its quarterly earnings results on Tuesday, February 25th. The company reported $1.19 EPS for the quarter, missing the consensus estimate of $1.23 by ($0.04). The company had revenue of $3.19 billion during the quarter, compared to analyst estimates of $3.25 billion. Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. Henry Schein's revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period in the prior year, the business posted $0.66 EPS. Equities analysts forecast that Henry Schein, Inc. will post 4.74 EPS for the current fiscal year.

Insider Transactions at Henry Schein

In other Henry Schein news, Director Philip A. Laskawy sold 2,604 shares of Henry Schein stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $71.04, for a total transaction of $184,988.16. Following the completion of the sale, the director now directly owns 24,805 shares in the company, valued at $1,762,147.20. This trade represents a 9.50 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Bradford C. Connett sold 4,036 shares of the business's stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $71.15, for a total transaction of $287,161.40. Following the completion of the sale, the chief executive officer now directly owns 62,688 shares in the company, valued at $4,460,251.20. This trade represents a 6.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.14% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have issued reports on HSIC shares. Bank of America raised shares of Henry Schein from an "underperform" rating to a "buy" rating and lifted their price target for the stock from $69.00 to $84.00 in a report on Monday, January 6th. Jefferies Financial Group boosted their target price on Henry Schein from $77.00 to $80.00 and gave the stock a "hold" rating in a research note on Thursday, January 23rd. Wells Fargo & Company assumed coverage on Henry Schein in a research note on Friday, February 14th. They set an "equal weight" rating and a $80.00 price target on the stock. UBS Group dropped their target price on shares of Henry Schein from $83.00 to $80.00 and set a "neutral" rating on the stock in a research report on Wednesday, February 26th. Finally, Mizuho assumed coverage on Henry Schein in a research report on Wednesday, December 4th. They issued a "neutral" rating and a $75.00 target price on the stock. Six analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $81.10.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.